請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7597
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 于明暉 | zh_TW |
dc.contributor.advisor | en | |
dc.contributor.author | 宋豐伃 | zh_TW |
dc.contributor.author | Feng-Yu Sung | en |
dc.date.accessioned | 2021-05-19T17:47:27Z | - |
dc.date.available | 2024-02-28 | - |
dc.date.copyright | 2018-10-11 | - |
dc.date.issued | 2018 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 1. Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119(8):1946-52.
2. Yu MW, You SL, Chang AS, et al. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991;51(20):5621-5. 3. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142(5):1140-1149.e3; quiz e13-4. 4. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347(3):168-74. 5. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118(3):554-9. 6. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97(4):265-72. 7. Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29(1):106-12. 8. Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141(4):1240-8, 1248.e1-2. 9. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100(16):1134-43. 10. Yuen MF, Fung SK, Tanaka Y, et al. Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and C. Journal of Clinical Microbiology 2004;42(11):5036. 11. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48 Suppl 1:S2-19. 12. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011-20. 13. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43(2 Suppl 1):S173-81. 14. Chen CJ, Yang HI, Su J, et al. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. In: Am Med Assoc; 2006, 65-73. 15. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678-86. 16. Orito E, Mizokami M, Ina Y, et al. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci U S A 1989;86(18):7059-62. 17. Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine 2005;23(19):2409-23. 18. Yu H, Yuan Q, Ge SX, et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I". PLoS One 2010;5(2):e9297. 19. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009;83(20):10538-47. 20. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25(6):1097-107. 21. Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003;124(4):925-32. 22. Chan HL, Tsui SK, Tse CH, et al. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis 2005;191(12):2022-32. 23. Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124(2):327-334. 24. Yin JH, Zhao J, Zhang HW, et al. HBV genotype C is independently associated with cirrhosis in community-based population. World J Gastroenterol 2010;16(3):379-83. 25. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005;43(3):411-7. 26. Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004;127(6):1733-8. 27. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53(10):1494-8. 28. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122(7):1756-62. 29. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004;72(3):363-9. 30. Orito E, Mizokami M, Sakugawa H, et al. A case‐control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 2001;33(1):218-223. 31. Lin CL, Liu CH, Chen W, et al. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22(7):1098-103. 32. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36(6):1425-30. 33. Sakugawa H, Nakasone H, Nakayoshi T, et al. Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. J Med Virol 2002;67(4):484-9. 34. Liu WC, Phiet PH, Chiang TY, et al. Five subgenotypes of hepatitis B virus genotype B with distinct geographic and virological characteristics. Virus Res 2007;129(2):212-23. 35. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26(2):177-82. 36. 周怡均. B型肝炎病毒基因CorePromoter和Precore區域之變異和肝細胞癌的關係:重疊病例對照研究 碩士論文 台灣大學流行病學研究所 2004. 37. 張儷瀞. B型肝炎病毒Surface基因和重疊Polymerase基因區域之突變頻譜和肝細胞癌危險性:重疊病例對照研究 碩士論文 台灣大學流行病學研究所 2004. 38. 鍾君明. B型肝炎病毒核基因序列變異與肝細胞癌之關係:重疊病例對照研究 碩士論文 台灣大學流行病學研究所 2006. 39. 藍珮文. B型肝炎病毒全基因序列變異與肝細胞癌危險性分析:重疊病例對照研究 碩士論文 台灣大學流行病學研究所 2007. 40. Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008;57(1):91-7. 41. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4(4):406-25. 42. 鄭郁青. 人類白血球抗原DRB基因多形性、B型肝炎病毒因子與肝細胞癌危險性:獨立與交互作用 碩士論文 台灣大學流行病學研究所 2003. 43. Luo M, Blanchard J, Brunham K, et al. Two-step high resolution sequence-based HLA-DRB typing of exon 2 DNA with taxonomy-based sequence analysis allele assignment. Hum Immunol 2001;62(11):1294-310. 44. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003;23(1):5-20. 45. Kalinina T, Iwanski A, Will H, et al. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003;38(5):1274-81. 46. Hou J, Wang Z, Cheng J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001;34(5):1027-34. 47. Maeng CY, Ryu CJ, Gripon P, et al. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. Virology 2000;270(1):9-16. 48. Milich DR, Jones JE, McLachlan A, et al. Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. II. Synthetic Pre-S(2) immunogen. J Immunol 1990;144(9):3544-51. 49. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60. 50. Sugauchi F, Ohno T, Orito E, et al. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 2003;70(4):537-44. 51. Chen BF, Liu CJ, Jow GM, et al. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006;130(4):1153-68. 52. Yeung P, Wong DK, Lai CL, et al. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 2011;203(5):646-54. 53. Qu LS, Liu JX, Liu TT, et al. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One 2014;9(5):e98257. 54. Hsieh YH, Su IJ, Wang HC, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004;25(10):2023-32. 55. Fan YF, Lu CC, Chen WC, et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001;33(1):277-86. 56. Nakatake H, Chisaka O, Yamamoto S, et al. Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication. Virology 1993;195(2):305-14. 57. Chami M, Ferrari D, Nicotera P, et al. Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. J Biol Chem 2003;278(34):31745-55. 58. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A 1994;91(22):10350-4. 59. Spandau DF, Lee CH. trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol 1988;62(2):427-34. 60. Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015;64(2):292-302. 61. Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. Journal of virology 1996;70(9):5845-5851. 62. Parekh S, Zoulim F, Ahn SH, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003;77(12):6601-12. 63. Tatsukawa M, Takaki A, Shiraha H, et al. Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer 2011;11:458. 64. Jang JW, Chun JY, Park YM, et al. Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci 2012;103(2):296-304. 65. Yeh CT, Shen CH, Tai DI, et al. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 2000;19(46):5213-20. 66. Kumar V, Jayasuryan N, Kumar R. A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc Natl Acad Sci U S A 1996;93(11):5647-52. 67. Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324(24):1705-9. 68. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006;193(9):1258-65. 69. Tong MJ, Blatt LM, Kao JH, et al. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int 2007;27(10):1356-63. 70. Akarca US, Greene S, Lok AS. Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members. Hepatology 1994;19(6):1366-70. 71. Karino Y, Toyota J, Sato T, et al. Early Mutation of Precore (A1896) Region Prior to Core Promoter Region Mutation Leads to Decrease of HBV Replication and Remission of Hepatic Inflammation. Digestive Diseases and Sciences 2000;45(11):2207-2213. 72. Chen WN, Oon CJ. Mutations and deletions in core promoter and precore stop codon in relation to viral replication and liver damage in Singaporean hepatitis B virus carriers. Eur J Clin Invest 2000;30(9):787-92. 73. Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31(5):1037-44. 74. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24 Suppl 1:3-10. 75. Bertoletti A, Southwood S, Chesnut R, et al. Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology 1997;26(4):1027-34. 76. Missale G, Redeker A, Person J, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 1993;177(3):751-62. 77. Ferrari C, Bertoletti A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991;88(1):214-22. 78. Cao T, Desombere I, Vanlandschoot P, et al. Characterization of HLA DR13-restricted CD4(+) T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. J Gen Virol 2002;83(Pt 12):3023-33. 79. Sallberg M, Ruden U, Magnius LO, et al. Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen. J Med Virol 1991;33(4):248-52. 80. Colucci G, Beazer Y, Cantaluppi C, et al. Identification of a major hepatitis B core antigen (HBcAg) determinant by using synthetic peptides and monoclonal antibodies. J Immunol 1988;141(12):4376-80. 81. Torre F, Cramp M, Owsianka A, et al. Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. J Med Virol 2004;72(3):370-6. 82. Liu Z, Luo K, He H, et al. Hot-spot mutations in hepatitis B virus core gene: eliciting or evading immune clearance? J Viral Hepat 2005;12(2):146-53. 83. Lee SM, Park SG, Park E, et al. The 113th and 117th charged amino acids in the 5th alpha-helix of the HBV core protein are necessary for pgRNA encapsidation. Virus Genes 2003;27(3):227-35. 84. Koschel M, Oed D, Gerelsaikhan T, et al. Hepatitis B virus core gene mutations which block nucleocapsid envelopment. J Virol 2000;74(1):1-7. 85. Sung FY, Jung CM, Wu CF, et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009;137(5):1687-97. 86. Zhu Y, Jin Y, Guo X, et al. Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2010;19(10):2623-30. 87. Kim DW, Lee SA, Hwang ES, et al. Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma. PLoS One 2012;7(10):e47372. 88. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27(6):1670-7. 89. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36(6):687-96. 90. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125(6):1714-22. 91. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125(2):292-7. 92. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48(3):750-8. 93. Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol 2009;24(8):1417-23. 94. Zhang X, Liu C, Gong Q, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterol Hepatol 2003;18(12):1353-7. 95. Wu Y, Gan Y, Gao F, et al. Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma. PLoS One 2014;9(5):e94864. 96. Tran A, Kremsdorf D, Capel F, et al. Emergence of and takeover by hepatitis B virus (HBV) with rearrangements in the pre-S/S and pre-C/C genes during chronic HBV infection. J Virol 1991;65(7):3566-74. 97. Bozkaya H, Ayola B, Lok AS. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology 1996;24(1):32-7. 98. Hannoun C, Horal P, Lindh M. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 2000;81(Pt 1):75-83. 99. Huang CJ, Wu CF, Lan CY, et al. Impact of genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression. PLoS One 2013;8(7):e70169. 100. Guo X, Jin Y, Qian G, et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol 2008;49(5):718-25. 101. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28(14):2437-44. 102. Hung YC, Lin CL, Liu CJ, et al. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. Hepatology 2014; 10.1002/hep.27610. 103. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28(10):1660-5. 104. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50(1):80-8. 105. Chen CH, Changchien CS, Lee CM, et al. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infect Dis 2008;198(11):1634-42. 106. Sung JJ, Tsui SK, Tse CH, et al. Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol 2008;82(7):3604-11. 107. Yin J, Xie J, Liu S, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol 2011;106(1):81-92. 108. Li X, Liu Y, Xu Z, et al. A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations. J Med Virol 2013;85(10):1698-704. 109. Mun HS, Lee SA, Kim H, et al. Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol 2011;85(1):123-32. 110. Li MS, Lau TC, Chan SK, et al. The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity. PLoS One 2011;6(7):e21856. 111. Kim S, Lee J, Ryu WS. Four conserved cysteine residues of the hepatitis B virus polymerase are critical for RNA pregenome encapsidation. J Virol 2009;83(16):8032-40. 112. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12(6):568-74. 113. Zhang M, Gong Y, Osiowy C, et al. Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis. Hepatology 2002;36(3):723-8. 114. Gauthier M, Bonnaud B, Arsac M, et al. Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome. J Clin Microbiol 2010;48(11):4207-15. 115. Gong L, Han Y, Chen L, et al. Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. J Clin Microbiol 2013;51(12):4087-94. 116. Capobianchi MR, Giombini E, Rozera G. Next-generation sequencing technology in clinical virology. Clin Microbiol Infect 2013;19(1):15-22. 117. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295(1):65-73. 118. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48(2):335-52. 119. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994;91(9):4077-81. 120. Delaney WEt, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003;77(21):11833-41. 121. Yuan TT, Shih C. A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L). J Virol 2000;74(10):4929-32. 122. Aurora R, Donlin MJ, Cannon NA, et al. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009;119(1):225-36. 123. Murray JM, Moenne-Loccoz R, Velay A, et al. Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks. PLoS One 2013;8(6):e67254. 124. Gobel U, Sander C, Schneider R, et al. Correlated mutations and residue contacts in proteins. Proteins 1994;18(4):309-17. 125. Eyal E, Frenkel-Morgenstern M, Sobolev V, et al. A pair-to-pair amino acids substitution matrix and its applications for protein structure prediction. Proteins 2007;67(1):142-53. 126. Wang YE, DeLisi C. Inferring protein-protein interactions in viral proteins by co-evolution of conserved side chains. Genome Inform 2006;17(1):23-35. 127. Lee BC, Park K, Kim D. Analysis of the residue-residue coevolution network and the functionally important residues in proteins. Proteins 2008;72(3):863-72. 128. Donlin MJ, Szeto B, Gohara DW, et al. Genome-wide networks of amino acid covariances are common among viruses. J Virol 2012;86(6):3050-63. 129. Cheng CP, Lee PF, Liu WC, et al. Analysis of precore/core covariances associated with viral kinetics and genotypes in hepatitis B e antigen-positive chronic hepatitis B patients. PLoS One 2012;7(2):e32553. 130. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13(11):2498-504. 131. Dong J, Horvath S. Understanding network concepts in modules. BMC Syst Biol 2007;1:24. 132. Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol 1992;66(7):4073-84. 133. Quarleri J. Core promoter: a critical region where the hepatitis B virus makes decisions. World J Gastroenterol 2014;20(2):425-35. 134. Kim HJ, Lee DH, Gwak GY, et al. Analysis of the core gene of hepatitis B virus in Korean patients. Liver Int 2007;27(5):633-8. 135. Kang HY, Lee S, Park SG, et al. Phosphorylation of hepatitis B virus Cp at Ser87 facilitates core assembly. Biochem J 2006;398(2):311-7. 136. Yuan TT, Sahu GK, Whitehead WE, et al. The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol 1999;73(7):5731-40. 137. Jones SA, Clark DN, Cao F, et al. Comparative Analysis of Hepatitis B Virus Polymerase Sequences Required for Viral RNA Binding, RNA Packaging, and Protein Priming. J Virol 2014;88(3):1564-72. 138. Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79(11):7269-72. 139. Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. J Virol 2004;78(15):7867-73. 140. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000;156(4):1117-32. 141. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85(1):16-23. 142. Maini MK, Boni C, Ogg GS, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999;117(6):1386-96. 143. Sobao Y, Tomiyama H, Sugi K, et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002;36(1):105-15. 144. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81(8):4215-25. 145. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77(1):68-76. 146. Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009;83(19):9652-62. 147. Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008;45(4):963-70. 148. Tzeng HT, Tsai HF, Liao HJ, et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012;7(6):e39179. 149. Xie Z, Chen Y, Zhao S, et al. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest 2009;38(7):624-38. 150. Aubert RD, Kamphorst AO, Sarkar S, et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A 2011;108(52):21182-7. 151. Zhang JY, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010;51(1):81-91. 152. Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177(1):739-47. 153. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41(4):771-8. 154. Zhao HQ, Li WM, Lu ZQ, et al. Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2014;20(24):7971-8. 155. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343(10):702-9. 156. Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39(Database issue):D913-9. 157. Wu YF, Wang LY, Lee TD, et al. HLA phenotypes and outcomes of hepatitis B virus infection in Taiwan. J Med Virol 2004;72(1):17-25. 158. Thio CL, Thomas DL, Karacki P, et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003;77(22):12083-7. 159. Ricci G, Colombo C, Ghiazza B, et al. HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects. Cancer Lett 1995;98(1):121-5. 160. Donaldson PT, Ho S, Williams R, et al. HLA class II alleles in Chinese patients with hepatocellular carcinoma. Liver 2001;21(2):143-8. 161. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41(5):591-5. 162. Mbarek H, Ochi H, Urabe Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet 2011;20(19):3884-92. 163. Li S, Qian J, Yang Y, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012;8(7):e1002791. 164. Hu L, Zhai X, Liu J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012;55(5):1426-31. 165. Thursz MR, Kwiatkowski D, Allsopp CE, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332(16):1065-9. 166. Hohler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997;26(3):503-7. 167. Ahn SH, Han KH, Park JY, et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000;31(6):1371-3. 168. Han YN, Yang JL, Zheng SG, et al. Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients. World J Gastroenterol 2005;11(36):5721-4. 169. Jiang YG, Wang YM, Liu TH, et al. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J Gastroenterol 2003;9(10):2221-5. 170. El-Chennawi FA, Auf FA, Metwally SS, et al. HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol Invest 2008;37(7):661-74. 171. Yoon JH, Shin S, In J, et al. Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants. Vaccine 2014;32(43):5638-44. 172. Maman Y, Blancher A, Benichou J, et al. Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins. J Virol 2011;85(9):4558-66. 173. Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296(5572):1439-43. 174. Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009;4(8):e6687. 175. Carlson JM, Listgarten J, Pfeifer N, et al. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol 2012;86(9):5230-43. 176. Gaudieri S, Rauch A, Park LP, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006;80(22):11094-104. 177. Rauch A, James I, Pfafferott K, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 2009;50(4):1017-29. 178. Timm J, Li B, Daniels MG, et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 2007;46(2):339-49. 179. Abbott WG, Tsai P, Leung E, et al. Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. J Virol 2010;84(1):621-9. 180. Kefalakes H, Budeus B, Walker A, et al. Adaptation of the hepatitis B virus core protein to CD8 T cell selection pressure. Hepatology 2015; 10.1002/hep.27771. 181. Desmond CP, Gaudieri S, James IR, et al. Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol 2012;86(2):1181-92. 182. Rayward-Smith APRaRdlIJ. Clustering Rules: A Comparison of Partitioning and Hierarchical Clustering Algorithms. Journal of Mathematical Modelling and Algorithms 2006;5(4):475–504. 183. Andersson T, Alfredsson L, Kallberg H, et al. Calculating measures of biological interaction. Eur J Epidemiol 2005;20(7):575-9. 184. Lai MJ, Wen SH, Lin YH, et al. Distributions of human leukocyte antigen-A, -B, and -DRB1 alleles and haplotypes based on 46,915 Taiwanese donors. Hum Immunol 2010;71(8):777-82. 185. Su WH, Hildesheim A, Chang YS. Human Leukocyte Antigens and Epstein–Barr Virus-Associated Nasopharyngeal Carcinoma: Old Associations Offer New Clues into the Role of Immunity in Infection-Associated Cancers. Front Oncol 2013;3. 186. Li X, Fasano R, Wang E, et al. HLA associations with nasopharyngeal carcinoma. Curr Mol Med 2009;9(6):751-65. 187. Magnusson PKE, Enroth H, Eriksson I, et al. Gastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res 2001;61(6):2684-9. 188. Cuzick J, Terry G, Ho L, et al. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000;82(7):1348-52. 189. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21(4):687-92. 190. Pan HF LD, Sun TH, Wang XJ. Association of HLA-DRB1 gene polymorphism and expression of DR antigen with primary hepatocellular carcinoma. CHINESE JOURNAL OF HEPATOBILIARY SURGERY 2009;5:357-361. 191. Fanning LJ, Levis J, Kenny-Walsh E, et al. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 2001;33(1):224-30. 192. Martin E, Carlson JM, Le AQ, et al. Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology 2014;11. 193. Miller RGJ. Simultaneous Statistical Inference. 2 ed: Springer-Verlag New York; 1981. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7597 | - |
dc.description.abstract | B型肝炎病毒相關肝細胞癌的致病機轉與宿主-病毒間複雜的交互作用高度相關。B型肝炎病毒因為使用缺乏校正功能的反轉錄酶複製,導致不同突變在慢性感染中因免疫選擇壓力而逐漸累積。B型肝炎病毒具有基因多樣性,以8%全基因體核苷酸序列差異為標準,至今已演化出10種基因型。基因型對於肝細胞癌的影響已有相當多的討論。即使在相同基因型,多個核苷酸改變或突變依然會在慢性B型肝炎感染中產生。本研究將探討B型肝炎病毒全基因體核苷酸序列突變圖譜與從健康B型肝炎帶原者到肝細胞癌發生過程的相關。另外,本研究也將偵測第二型人類白血球抗原對病毒變異的影響,與兩者間交互作用對肝細胞癌發生的影響。所有分析資料利用巢式病例對照研究,個案來自4841名男性B型肝炎表面抗原帶原者追蹤22年的世代。本研究共分為三個主題,包括:
(I) HBV全基因體單點核苷酸變異與肝細胞癌發展之關係 本研究第一部分為調查B型肝炎病毒變異與肝細胞發展之時序相關。使用巢式病例對照研究中117位肝細胞癌與118位對照個案,其基線血液檢體(距診斷肝細胞癌時間前<1-20年)的病毒全基因體序列資料。 我們發現31個病毒單核苷多型性(SNP)與肝細胞癌發展有相關。接著利用2015年11月30日對GenBank資料庫系統性收集的B型肝炎病毒全基因體序列進行驗證。共有11個與肝細胞癌發展相關的病毒SNPs在二個資料庫中皆有一致的結果。接著將11個病毒變異加總組成突變分數,發現突變分數會隨著肝細胞癌診斷時間間距越近而上升,突變分數1、2、3、≥4相對於沒有任何病毒變異其調整基因型後的相對危險性分別為2.61、4.97、7.38和23.42。在肝細胞癌發病前<4.5年內,突變分數對肝細胞癌罹病風險的鑑別力優於病毒量、病毒基因型和其他各種危險因子的組合(B基因型或/及C基因型的接收者特徵曲線下面積=0.83–0.89;敏感度=72.7%–94.1%;特異度=58.3%–70.5%)。 本研究是第一篇前瞻性地評估B型肝炎全基因體突變圖譜與肝細胞癌的相關,並發展一組突變圖譜可早期預測肝細胞癌發生,以應用於監測慢性B型感染到肝細胞癌發生的進程。 (II) HBV全基因體單點核苷酸變異之共變網絡與肝細胞癌發展之關係 第一部分研究視每個核苷酸變異與病毒上的其它變異各自獨立,然而,許多變異會因為互補變異或生物功能而互有連結。本論文的第二部分研究接續上述巢式病例對照研究,對B型肝炎病毒全基因體單點核苷酸變異使用共變網絡分析探討變異之間的演化在不同基因型、慢性B型肝炎感染自然史階段(免疫耐受期、免疫廓清期、不活化殘餘期、e抗原陰性肝炎期)和肝細胞癌疾病狀態的關係。我們特別針對核苷酸成對間的交互作用(共變),包含其個數和強度(共變分數)探討分析。 在病毒全基因體569個變異比率>4%的核苷酸中,B基因型共產生248個(43.6%)共變位置,C基因型產生222個(39.0%)。不管在哪個基因型,平均共變分數顯著在HBeAg陰轉後上升(p<0.0001)。不活化殘餘期的共變網絡為軸輻式網絡結構,網絡異質性為0.972-1.076,其擁有最多連結的樞紐核苷酸位置與免疫耐受期和免疫廓清期明顯不同。整體來說,大部分(B基因型:69.8%,C基因型:55.4%)形成共變的核苷酸為基因型特異的核苷酸。然而,在C基因型非基因型特異的核苷酸共變對中,肝細胞癌相較於對照組有較高的共變分數(共變分數S: 2.14 vs. 1.14,p<0.0001)。另外,發現一個只在B基因型對照組出現、由X基因與precore基因上12個核苷酸組成的共變次網絡,網絡中8個變異與低病毒量顯著相關。 共變網絡分析可提供肝細胞癌發展過程中病毒演化研究的另一種角度。而與其它核苷酸變異高度連結的樞紐核苷酸可能可以做為抗病毒藥物的目標。 (III) HLA-DRB1多型性、HBV病毒變異、與肝細胞癌發展之關係 B型肝炎病毒變異的產生來自於逃脫宿主免疫壓力,而病毒與宿主免疫之間的互相作用影響著肝臟疾病的發展。過去許多研究發現人類白血球抗原多型性與B型肝炎進程和病毒清除有關,但是是與哪個特定人類白血球抗原基因座相關仍有不同的看法。本研究的第三部分針對34種第二型人類白血球抗原DRB1基因4位編碼的基因型,探討人類白血球抗原多型性與肝細胞癌的相關。考慮相關背後的可能機轉,再進一步分析DRB1對偶基因對病毒突變的影響,特別針對抗原決定位與上述兩者對肝細胞癌的交互作用討論。 在巢式病例對照研究資料庫156位肝細胞癌與233位對照個案中,發現2種DRB1基因型與肝細胞癌發生有關,DRB1*08032 (相對危險性=2.11,p=0.0148)和DRB1*1401(相對危險性=0.40,p=0.0216)。而DRB1*15011則在病毒量>4 log copies/mL族群中與肝細胞癌發生正相關(相對危險性=2.44,p=0.0295)。再利用同時有病毒序列及HLA-DRB1對偶基因分型資料的105位肝細胞癌與89位對照個案,針對10種DRB1基因分型頻率>5%進行分析,總共發現210個DRB1和病毒變異的顯著相關,包含182個核苷酸位置。高達83.3%篩選出的核苷酸為適應型,與特定人類白血球抗原基因相關,這些核苷酸大多位於已知抗原決定位上和基因無重疊之區域中。無觀察到DRB1基因分型與病毒核肝酸變異對肝細胞癌發生的交互作用。 本研究顯示帶有特定DRB1對偶基因分型會影響肝細胞癌發生。被DRB1對偶基因篩選出的病毒變異其生物機轉需再進一步探討。 | zh_TW |
dc.description.abstract | The pathogenesis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) involves complicated host-virus interaction. The reverse transcriptase of the virus lacks proofreading function, leading to different mutations accumulating in the viral genome during long-term persistent infection under different immune selection pressures. HBV is genetically diverse and has evolved into ten genotypes defined by more than 8% of divergence in the entire nucleotide sequence. Their impacts on the risk of HCC are well documented. Even within the same genotype; however, multiple nucleotide substitutions or mutations can arise throughout the viral genome during chronic HBV infection. This study was designed to detect HBV whole-genome mutation profile in association with progression from healthy HBV carrier state to HCC. We also aimed to determine the effect of human leukocyte antigen (HLA) class II alleles on the generation of viral mutations, and their interactions on the development of HCC. All analyses were conducted using data from a case-control study nested within a population-based cohort consisting of 4841 male hepatitis B surface antigen (HBsAg) carriers with 22-years of follow-up. This dissertation is divided into three parts.
(I) The associations between HBV-single nucleotide polymorphisms (SNPs) among the whole-genome and HCC development In part 1, we investigated the temporality of different HBV mutations in blood and the development of HCC. Using HBV whole genome sequence data obtained from<1 to 20 years before HCC diagnosis from 117 HCC cases and 118 controls in a nested case-control study. We identified 31 HCC-associated HBV-SNPs. Then we conducted a systemic search of GenBank database through November 30, 2015 to identify HBV full-length sequences to seek supportive evidence. Eleven of which could be obtained similar results with the GenBank database in accordance with results obtained from the nested case-control study. Furthermore, we found that a simple-count mutation score using the 11 HBV-SNPs increased with time approaching HCC diagnosis. The multivariate-adjusted odds ratios (ORs) associated with HCC were 2.61, 4.97, 7.38 and 23.42, respectively, for the mutation score of 1, 2, 3, and ≥4, as compared with the group without any of the HBV-SNPs. Within time to diagnosis of less than 4.5 years, the mutation score for HCC risk prediction outperformed HBV DNA, genotype, and other combination of risk factors ( area under the receiver operating characteristic curve=0.83-0.89, sensitivity=72.7%-94.1%, specificity=58.3%-70.5% for predominant genotype B and/or C in Taiwan). Our study is the first to prospectively evaluate the association between HBV mutation profiling and HCC risk, and developed mutation score can be used as a short-term risk score for monitoring of hepatitis B progression to HCC. (II) The associations between genome-wide HBV nucleotide covariance networks and HCC development The first part of study treated variation at each nucleotide position as being independent from all others in the viral genome. However, different mutations may interact due to compensatory variation or functional linkage. In part 2 of the dissertation, we conducted genome-wide covariance network analysis of HBV nucleotide sequence to assess coordinated evolution by HBV genotype, distinct clinical phases (i.e., immune-tolerant, immune-clearance, non-/low- replicative, and hepatitis B e antigen (HBeAg)-negative hepatitis phase) of chronic HBV infection, and HCC status in the aforementioned nested case-control study. We addressed the pairwise interactions (covariances), including their number and strength (covariance score). Among 569 nucleotide positions with frequencies >4%, genotype B had 248 (43.6%) covariant positions, and 222 (39.0%) were found for genotype C. Regardless of HBV genotype, the average covariance score increased after HBeAg seroconversion (p<0.0001). For non-/low- replicative phase, the covariance network had a hub-and-spoke architecture, with heterogeneity ranging about 0.972 to 1.076 and top hubs that differed from those observed in immune-tolerant or immune-clearance phase. Overall, the majority (69.8% for genotype B; 55.4% for genotype C) of the nucleotide positions that formed the covarying pairs were genotype-dependent. However, HCC cases had higher average covariance score for genotype-independent covarying positions than controls in genotype C subjects (S value: 2.14 vs. 1.14, p<0.0001). Besides, a sub-covariance network composed of 12 HBV-SNPs in X or precore gene was found in genotype B controls, there were significant negative associations between 8 of which and HBV DNA. The covariance network analysis may provide insights into viral evolution during HCC development, and the highly connected hubs that have a large number of functional interactions with other nucleotides positions may be valuable antiviral drug targets. (III) HLA-DRB1 polymorphism, HBV mutation, and HCC development Mutations in HBV genome contribute to its escape from host immune response and the interplay of the virus and the host immune response is likely to result in hepatic disease progression. Polymorphisms of HLA have been associated with hepatitis B progression and viral clearance, although the evidence for a link with specific HLA loci is controversial. In part 3 of the study, we first examined the association between HLA polymorphism and HBV-related HCC risk, focusing in particular on HLA-DRB1 alleles, for which 34 alleles were classified by four-digit allele genotyping. We then considered potential mechanisms underlying the association, and evaluated the impact of HLA-DRB1 alleles on viral mutations, especially specific epitopes, and their interactions in HCC. In a nested case-control study of 156 HCC cases and 233 controls, HCC risk was associated with two DRB1 alleles, DRB1*08032 (OR=2.11, p=0.0148) and DRB1*1401 (OR=0.40, p=0.0216) in overall, while DRB1*15011 was associated with HCC in subjects with HBV DNA >4 log copies/mL (OR=2.44, p=0.0295). Next, using HBV sequence and HLA-DRB1 allelic data from 105 HCC cases and 89 controls, 210 associations between the HLA-DRB1 type and HBV-SNPs among 10 DRB1 alleles with frequencies >5% were identified at 182 sites in the HBV genome. 83.3% of HBV-SNPs were adapted form associated with a given HLA allele, and most of them were located in known HBV epitopes and non-overlapping regions of genes. No interactions between HLA-DRB1 alleles and HBV-SNPs on HCC risk were observed. The present study showed that specific HLA-DRB1 alleles could influence the susceptibility of HCC. The biological function of HBV-SNPs selected by DRB1 alleles needs to be further investigated. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T17:47:27Z (GMT). No. of bitstreams: 1 ntu-107-D98842005-1.pdf: 5757103 bytes, checksum: 1824fda4e85f65a23732e852de3fdd33 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書......................................................................................................................i
誌謝................................................................................................................................ii 中文摘要...........................................................................................................................iii Abstract...........................................................................................................................vi 表目錄............................................................................................................................xiii 圖目錄.............................................................................................................................xiv 第一章 緒論.........................................................................................................................1 第二章 研究目的.....................................................................................................................3 第三章 資料庫.......................................................................................................................4 第四章 HBV全基因體單點核苷酸變異與肝細胞癌發展之關係..................................................................................14 第一節 研究背景....................................................................................................................14 第二節 材料與方法..................................................................................................................17 第三節 研究結果....................................................................................................................17 第四節 討論.......................................................................................................................19 第五章 HBV全基因體單點核苷酸變異之共變網絡與肝細胞癌發展之關係........................................................................30 第一節 研究背景...................................................................................................................30 第二節 材料與方法.................................................................................................................31 第三節 研究結果...................................................................................................................33 第四節 討論.......................................................................................................................36 第六章 HLA-DRB1多型性、HBV病毒變異、與肝細胞癌發展之關係…............................................................................56 第一節 研究背景...................................................................................................................56 第二節 材料與方法.................................................................................................................58 第三節 研究結果...................................................................................................................59 第四節 討論......................................................................................................................61 第七章 結論......................................................................................................................75 參考文獻...........................................................................................................................76 | - |
dc.language.iso | zh_TW | - |
dc.title | B型肝炎病毒全基因突變圖譜、人類白血球抗原遺傳多型性、與肝細胞癌之關係 | zh_TW |
dc.title | Hepatitis B Virus Whole Genome Mutation Profiling, HLA Genetic Polymorphism, and Hepatocellular Carcinoma | en |
dc.type | Thesis | - |
dc.date.schoolyear | 106-2 | - |
dc.description.degree | 博士 | - |
dc.contributor.oralexamcommittee | 劉俊人;楊雅倩;莊雅惠;林志陵 | zh_TW |
dc.contributor.oralexamcommittee | ;;; | en |
dc.subject.keyword | B型肝炎病毒全基因體,變異圖譜,共變網絡,人類白血球抗原,B型肝炎感染,肝細胞癌, | zh_TW |
dc.subject.keyword | HBV whole genome,mutation profiling,covariance network,human leukocyte antigen,hepatitis B infection,hepatocellular carcinoma, | en |
dc.relation.page | 86 | - |
dc.identifier.doi | 10.6342/NTU201800715 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2018-05-16 | - |
dc.contributor.author-college | 公共衛生學院 | - |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
dc.date.embargo-lift | 2028-12-31 | - |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-2.pdf 目前未授權公開取用 | 5.62 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。